Head of Investor Relations Welcome to the Q4 and full year 2024 conference call for investors and analysts. As usual, you can find the slides on sanofi.com. Please turn to Slide 3. Here we have the ...

That gives it an advantage over other biologics for severe asthma, such as Sanofi/Regeneron's IL-4/IL-13 inhibitor Dupixent (dupilumab ... has attributed to complex administration and a demanding ...

the US FDA has approved Sanofi and Regeneron's Dupixent (dupilumab) for COPD - as has China's National Medical Products Administration (NMPA), which announced its approval the same day.

In contrast, the increased release of IL-4 by basophils following the administration of the glycoprotein IPSE ... are being treated with biologics that block the IL-4/IL-13 axis (e.g., dupilumab, an ...

Enveda, a biotechnology company using AI to translate nature into new medicines, is proud to announce testing of its lead asset, ENV-294, in a second indication: asthma. This novel therapeutic, ...

Teaser: Off-label systemic agents may treat inflammatory autoimmune vulvar diseases such as lichen sclerosus and lichen ...

The international consulting firm Clarivate makes its bet among the novelties ready for the medicine cabinet this year: three ...

A 28-year-old woman developed allergic contact dermatitis within 6 to 24 hours exclusively after using carmine-containing eyeshadows and lipsticks. She had both a positive patch test result and a ...

He serves with Vice President J.D. Vance (R), a former senator from Ohio. This page provides an overview of Trump's second presidential administration, including top officials and personnel and key ...

CYP shows a carcinogenic and teratogenic activity (86). As a result CYP administration is not allowed in pregnancy and breastfeeding (101). Moreover, temporary or permanent gonadal dysfunction has ...